Lyell Immunopharma Inc (LYEL)
2.54
+0.14
(+5.83%)
USD |
NASDAQ |
May 14, 14:20
Lyell Immunopharma Free Cash Flow (Quarterly): -42.05M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -42.05M |
| December 31, 2023 | -40.66M |
| September 30, 2023 | -37.88M |
| June 30, 2023 | -40.09M |
| March 31, 2023 | -47.74M |
| December 31, 2022 | -44.85M |
| September 30, 2022 | -39.89M |
| June 30, 2022 | -51.50M |
| March 31, 2022 | -57.58M |
| Date | Value |
|---|---|
| December 31, 2021 | -43.48M |
| September 30, 2021 | -37.09M |
| June 30, 2021 | -58.39M |
| March 31, 2021 | -52.79M |
| December 31, 2020 | -51.61M |
| September 30, 2020 | -34.27M |
| June 30, 2020 | -96.00M |
| March 31, 2020 | -30.47M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-96.00M
Minimum
Jun 2020
-30.47M
Maximum
Mar 2020
-47.43M
Average
-43.48M
Median
Dec 2021
Free Cash Flow (Quarterly) Benchmarks
| GlycoMimetics Inc | -10.52M |
| Candel Therapeutics Inc | -7.469M |
| Eliem Therapeutics Inc | -0.947M |
| Entrada Therapeutics Inc | -26.36M |
| NovaBay Pharmaceuticals Inc | -0.316M |